Compare BridgeBio Pharma Inc (BBIO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Prudential Financial Inc — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while Prudential Financial Inc trades at $114.8 (market cap $39.87B). The key difference: Prudential Financial Inc is far larger — about 2.4× BridgeBio Pharma Inc's market cap, and Prudential Financial Inc pays a 4.88% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PRU | |
|---|---|---|
Market Cap | $16.46B | $39.87B |
Sector | Health | Financials |
52-Week High | $90.17 | $118.72 |
52-Week Low | $44.81 | $92.00 |
Enterprise Value | $18.02B | $66.92B |
Dividend Yield | — | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
PRU trades at $116.17, up 0.69% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 11.96, net income margin of 5.5%, and recent earnings beats in Q3 2025 and Q1 2026. Recent news highlights dividend payments and expansion into India's life insurance market.
The outlook is mixed; solid profitability and low valuation support upside, but analyst consensus is cautious with a $102.50 price target below current levels. Key risks include volatile cash flows and high debt levels. Earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
